JP2005502584A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005502584A5 JP2005502584A5 JP2002555103A JP2002555103A JP2005502584A5 JP 2005502584 A5 JP2005502584 A5 JP 2005502584A5 JP 2002555103 A JP2002555103 A JP 2002555103A JP 2002555103 A JP2002555103 A JP 2002555103A JP 2005502584 A5 JP2005502584 A5 JP 2005502584A5
- Authority
- JP
- Japan
- Prior art keywords
- erythropoietin
- modified
- molecule
- use according
- sugar chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 212
- 229940105423 erythropoietin Drugs 0.000 claims 210
- 102000003951 Erythropoietin Human genes 0.000 claims 205
- 108090000394 Erythropoietin Proteins 0.000 claims 205
- 125000003277 amino group Chemical group 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 14
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 12
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 10
- 210000004962 mammalian cell Anatomy 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 210000001519 tissue Anatomy 0.000 claims 9
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims 8
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims 8
- 108010027485 asialoerythropoietin Proteins 0.000 claims 8
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 8
- 230000013595 glycosylation Effects 0.000 claims 8
- 238000006206 glycosylation reaction Methods 0.000 claims 8
- 231100000252 nontoxic Toxicity 0.000 claims 8
- 230000003000 nontoxic effect Effects 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 8
- 235000001014 amino acid Nutrition 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 7
- 150000001510 aspartic acids Chemical class 0.000 claims 7
- 230000004888 barrier function Effects 0.000 claims 7
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 7
- 125000000837 carbohydrate group Chemical group 0.000 claims 7
- 238000003776 cleavage reaction Methods 0.000 claims 7
- 229960003067 cystine Drugs 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 230000007017 scission Effects 0.000 claims 7
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 7
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 7
- 210000000056 organ Anatomy 0.000 claims 6
- 108010075944 Erythropoietin Receptors Proteins 0.000 claims 4
- 102100036509 Erythropoietin receptor Human genes 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 210000002889 endothelial cell Anatomy 0.000 claims 4
- 230000000913 erythropoietic effect Effects 0.000 claims 4
- 102000008300 Mutant Proteins Human genes 0.000 claims 3
- 108010021466 Mutant Proteins Proteins 0.000 claims 3
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 3
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 230000000844 anti-bacterial effect Effects 0.000 claims 3
- -1 antibody Substances 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940041181 antineoplastic drug Drugs 0.000 claims 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 229940088597 hormone Drugs 0.000 claims 3
- 239000005556 hormone Substances 0.000 claims 3
- 239000003018 immunosuppressive agent Substances 0.000 claims 3
- 229940124589 immunosuppressive drug Drugs 0.000 claims 3
- 239000003900 neurotrophic factor Substances 0.000 claims 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims 3
- 239000012217 radiopharmaceutical Substances 0.000 claims 3
- 229940121896 radiopharmaceutical Drugs 0.000 claims 3
- 230000002799 radiopharmaceutical effect Effects 0.000 claims 3
- 239000000018 receptor agonist Substances 0.000 claims 3
- 229940044601 receptor agonist Drugs 0.000 claims 3
- 239000002464 receptor antagonist Substances 0.000 claims 3
- 229940044551 receptor antagonist Drugs 0.000 claims 3
- 241000894007 species Species 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 230000035899 viability Effects 0.000 claims 3
- ZGCHLOWZNKRZSN-NTSWFWBYSA-N 3-deoxyglucosone Chemical compound OC[C@@H](O)[C@@H](O)CC(=O)C=O ZGCHLOWZNKRZSN-NTSWFWBYSA-N 0.000 claims 2
- UHPMJDGOAZMIID-UHFFFAOYSA-N 3-deoxyglucosone Natural products OCC1OC(O)C(=O)CC1O UHPMJDGOAZMIID-UHFFFAOYSA-N 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- BFSYFTQDGRDJNV-AYHFEMFVSA-N fructosyllysine Chemical compound OC(=O)[C@@H](N)CCCCNCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BFSYFTQDGRDJNV-AYHFEMFVSA-N 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010057430 Retinal injury Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 210000004404 adrenal cortex Anatomy 0.000 claims 1
- 210000001943 adrenal medulla Anatomy 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 210000002937 blood-testis barrier Anatomy 0.000 claims 1
- 150000001718 carbodiimides Chemical class 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 claims 1
- 125000005594 diketone group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000005168 endometrial cell Anatomy 0.000 claims 1
- 210000003989 endothelium vascular Anatomy 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000028023 exocytosis Effects 0.000 claims 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical group NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 102000044890 human EPO Human genes 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000003169 placental effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 208000032253 retinal ischemia Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims 1
- NCGJACBPALRHNG-UHFFFAOYSA-M sodium;2,4,6-trinitrobenzenesulfonate Chemical group [Na+].[O-][N+](=O)C1=CC([N+]([O-])=O)=C(S([O-])(=O)=O)C([N+]([O-])=O)=C1 NCGJACBPALRHNG-UHFFFAOYSA-M 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 230000032258 transport Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25924500P | 2000-12-29 | 2000-12-29 | |
| US09/753,132 US6531121B2 (en) | 2000-12-29 | 2000-12-29 | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| PCT/US2001/049479 WO2002053580A2 (en) | 2000-12-29 | 2001-12-28 | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009209009A Division JP2010031017A (ja) | 2000-12-29 | 2009-09-10 | エリスロポエチン応答性細胞、組織及び器官の保護、回復ならびに増強 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005502584A JP2005502584A (ja) | 2005-01-27 |
| JP2005502584A5 true JP2005502584A5 (https=) | 2005-12-22 |
Family
ID=26947185
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002555103A Pending JP2005502584A (ja) | 2000-12-29 | 2001-12-28 | エリスロポエチン応答性細胞、組織及び器官の保護、回復ならびに増強 |
| JP2009209009A Pending JP2010031017A (ja) | 2000-12-29 | 2009-09-10 | エリスロポエチン応答性細胞、組織及び器官の保護、回復ならびに増強 |
| JP2013092598A Expired - Fee Related JP6114099B2 (ja) | 2000-12-29 | 2013-04-25 | エリスロポエチン応答性細胞、組織及び器官の保護、回復ならびに増強 |
| JP2015141106A Pending JP2015221816A (ja) | 2000-12-29 | 2015-07-15 | エリスロポエチン応答性細胞、組織及び器官の保護、回復ならびに増強 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009209009A Pending JP2010031017A (ja) | 2000-12-29 | 2009-09-10 | エリスロポエチン応答性細胞、組織及び器官の保護、回復ならびに増強 |
| JP2013092598A Expired - Fee Related JP6114099B2 (ja) | 2000-12-29 | 2013-04-25 | エリスロポエチン応答性細胞、組織及び器官の保護、回復ならびに増強 |
| JP2015141106A Pending JP2015221816A (ja) | 2000-12-29 | 2015-07-15 | エリスロポエチン応答性細胞、組織及び器官の保護、回復ならびに増強 |
Country Status (33)
| Country | Link |
|---|---|
| EP (2) | EP2281828A3 (https=) |
| JP (4) | JP2005502584A (https=) |
| KR (3) | KR20080041755A (https=) |
| CN (2) | CN1505638A (https=) |
| AR (1) | AR035412A1 (https=) |
| AU (1) | AU2002239665B2 (https=) |
| BG (1) | BG108030A (https=) |
| BR (1) | BR0116587A (https=) |
| CA (1) | CA2432853A1 (https=) |
| CL (1) | CL2010000606A1 (https=) |
| CZ (1) | CZ20032059A3 (https=) |
| DO (1) | DOP2001000321A (https=) |
| EA (1) | EA007967B1 (https=) |
| EE (1) | EE200300267A (https=) |
| ES (1) | ES2564552T3 (https=) |
| HR (1) | HRP20030515A2 (https=) |
| HU (1) | HUP0302549A3 (https=) |
| IL (2) | IL156399A0 (https=) |
| IS (1) | IS6843A (https=) |
| MX (1) | MXPA03005893A (https=) |
| NO (1) | NO332038B1 (https=) |
| NZ (2) | NZ526722A (https=) |
| PA (1) | PA8536201A1 (https=) |
| PE (2) | PE20020744A1 (https=) |
| PH (1) | PH12016500941A1 (https=) |
| PL (1) | PL365876A1 (https=) |
| RS (1) | RS52276B (https=) |
| SK (1) | SK9572003A3 (https=) |
| SV (1) | SV2003000814A (https=) |
| UA (1) | UA91321C2 (https=) |
| UY (1) | UY27111A1 (https=) |
| WO (1) | WO2002053580A2 (https=) |
| ZA (1) | ZA200304551B (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
| US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
| US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| EP1930023A3 (en) * | 2001-04-09 | 2008-08-06 | East Carolina University | Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| PT1465987E (pt) | 2001-12-07 | 2008-04-15 | Crucell Holland Bv | Produção de vírus, isolados virais e vacinas |
| DE10219545A1 (de) * | 2002-04-26 | 2003-11-06 | Lang Florian | Regulation der Apoptose |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| NZ542094A (en) | 2003-03-14 | 2008-12-24 | Neose Technologies Inc | Branched polymer conjugates comprising a peptide and water-soluble polymer chains |
| PL1615945T3 (pl) | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| JP2007523630A (ja) | 2003-05-09 | 2007-08-23 | ネオス テクノロジーズ インコーポレイテッド | ヒト成長ホルモングリコシル化突然変異体の組成と調合法 |
| WO2004099396A1 (en) | 2003-05-09 | 2004-11-18 | Crucell Holland B.V. | Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| WO2005032467A2 (en) * | 2003-09-29 | 2005-04-14 | Warren Pharmaceuticals, Inc. | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
| US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| NZ548123A (en) | 2004-01-08 | 2010-05-28 | Novo Nordisk As | O-linked glycosylation of peptides |
| US20080305990A1 (en) * | 2004-07-02 | 2008-12-11 | The Kenneth S Warren Institute, Inc. | Method of Producing Fully Carbamylated Erythropoietin |
| WO2006002646A2 (en) * | 2004-07-07 | 2006-01-12 | H. Lundbeck A/S | Novel carbamylated epo and method for its production |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| AT500929B1 (de) | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | Pharmazeutische zubereitung die erythropoietin enthält |
| CN101090973B (zh) * | 2004-12-30 | 2012-03-28 | 克鲁塞尔荷兰公司 | 从表达腺病毒e1a蛋白的细胞中获得唾液酸化增加的重组蛋白质的方法及由此获得的蛋白质 |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| CA2595676A1 (en) * | 2005-01-25 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
| WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| EP2975135A1 (en) | 2005-05-25 | 2016-01-20 | Novo Nordisk A/S | Glycopegylated factor IX |
| SI2540309T1 (en) | 2005-08-05 | 2018-04-30 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and their uses |
| JPWO2007020922A1 (ja) * | 2005-08-17 | 2009-02-26 | 創 戸苅 | 脳疾患の治療剤および予防剤 |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| EP1978030A4 (en) | 2006-01-18 | 2009-12-30 | Chugai Pharmaceutical Co Ltd | PROCESS FOR REMOVING SIALIC ACID AND METHOD FOR PRODUCING ASIALOERYTHROPOIETIN |
| EP2049144B8 (en) | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylation of peptides via o-linked glycosylation sequences |
| EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES |
| AR065613A1 (es) * | 2007-03-09 | 2009-06-17 | Chugai Pharmaceutical Co Ltd | Agentes de proteccion para organos transplantados |
| HRP20130382T1 (hr) | 2007-04-03 | 2013-05-31 | Biogenerix Ag | Postupci lijeäśenja pomoä†u glikopegiliranog g-csf |
| CA2690611C (en) | 2007-06-12 | 2015-12-08 | Novo Nordisk A/S | Improved process for the production of nucleotide sugars |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| KR20200075044A (ko) | 2008-01-22 | 2020-06-25 | 아라임 파마슈티칼즈, 인크. | 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 |
| WO2009102021A1 (ja) * | 2008-02-14 | 2009-08-20 | Kyoto University | 骨髄由来幹細胞、前駆細胞機能賦活による網膜疾患治療 |
| PL2257311T3 (pl) | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Koniugaty cząsteczek czynnika VIII |
| EP2297197B1 (en) * | 2008-05-29 | 2012-03-07 | HanAll Biopharma Co., Ltd. | Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof |
| BR122012024318A2 (pt) | 2008-09-26 | 2019-07-30 | Ambrx, Inc. | Polipeptídeos modificados de eritropoetina animal e seus usos |
| WO2012003960A1 (en) | 2010-07-06 | 2012-01-12 | Augustinus Bader | Topical application of erythropoietin for the treatment of eye disorders and injuries |
| US12565524B2 (en) | 2012-05-29 | 2026-03-03 | North Carolina Central University | Methods for the production of cytoprotective asialo-erythropoietin in plants and its purification from plant tissues |
| JP2019523633A (ja) | 2016-04-29 | 2019-08-29 | アライム ファーマシューティカルズ，インコーポレーテッド | 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド |
| JP2019532618A (ja) * | 2016-07-12 | 2019-11-14 | ヘキサル・アクチェンゲゼルシャフト | 低アセチル化率シアル酸残基を有する糖タンパク質 |
| RU2709833C1 (ru) * | 2019-06-13 | 2019-12-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ коррекции микроциркуляции в плаценте асиалированным эритропоэтином при ADMA-подобной модели преэклампсии |
| RU2707060C1 (ru) * | 2019-06-14 | 2019-11-21 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ коррекции эндотелиальной дисфункции асиалированным эритропоэтином при ADMA-подобной модели преэклампсии |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US4835260A (en) | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
| JPH029900A (ja) * | 1988-04-12 | 1990-01-12 | Kirin Amgen Inc | 修飾エリスロポエチン |
| US5308617A (en) * | 1988-08-10 | 1994-05-03 | Halzyme Ltd. | Protein heparin conjugates |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| DE3923963A1 (de) | 1989-07-20 | 1991-01-31 | Behringwerke Ag | Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung |
| WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| KR100221066B1 (ko) * | 1989-10-13 | 1999-10-01 | 스튜어트 엘.왓트 | 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물 |
| US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
| EP0945515A3 (en) | 1989-11-06 | 2002-08-21 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
| JP3156236B2 (ja) * | 1991-09-30 | 2001-04-16 | 雪印乳業株式会社 | 記憶障害改善治療剤 |
| PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
| US5625035A (en) * | 1992-06-05 | 1997-04-29 | The Regents, University Of California | Erythropoietin binding protein from mammalian serum |
| US6153407A (en) * | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| CN1057534C (zh) | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | 促红细胞生成素类似物 |
| US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
| US5830851A (en) | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
| US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
| KR100353115B1 (ko) | 1995-11-13 | 2003-01-06 | 다카라츠죠 가부시키가이샤 | 레트로바이러스를사용한표적세포내로의유전자도입방법 |
| US5856292A (en) | 1996-04-08 | 1999-01-05 | Colgate Palmolive Company | Light duty liquid cleaning compositions |
| US5835382A (en) | 1996-04-26 | 1998-11-10 | The Scripps Research Institute | Small molecule mimetics of erythropoietin |
| AU721196B2 (en) | 1996-10-25 | 2000-06-29 | G.D. Searle & Co. | Circularly permuted erythropoietin receptor agonists |
| DE19857609A1 (de) * | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| CA2359345A1 (en) * | 1999-01-14 | 2000-07-20 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| KR101012932B1 (ko) * | 1999-04-13 | 2011-02-08 | 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 | 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법 |
| PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| KR20130099071A (ko) | 2010-08-25 | 2013-09-05 | 액세스 비지니스 그룹 인터내셔날 엘엘씨 | 무선 전원 공급 시스템 및 다층 심 조립체 |
| KR101290029B1 (ko) | 2011-01-20 | 2013-07-30 | 에스티팜 주식회사 | 시타글립틴의 중간체 제조방법 |
-
2001
- 2001-12-27 PA PA20018536201A patent/PA8536201A1/es unknown
- 2001-12-28 NZ NZ526722A patent/NZ526722A/en not_active IP Right Cessation
- 2001-12-28 CA CA002432853A patent/CA2432853A1/en not_active Abandoned
- 2001-12-28 AU AU2002239665A patent/AU2002239665B2/en not_active Ceased
- 2001-12-28 CZ CZ20032059A patent/CZ20032059A3/cs unknown
- 2001-12-28 HU HU0302549A patent/HUP0302549A3/hu not_active Application Discontinuation
- 2001-12-28 CN CNA018229492A patent/CN1505638A/zh active Pending
- 2001-12-28 EA EA200300738A patent/EA007967B1/ru not_active IP Right Cessation
- 2001-12-28 KR KR1020087010285A patent/KR20080041755A/ko not_active Ceased
- 2001-12-28 KR KR1020037008843A patent/KR100880201B1/ko not_active Expired - Fee Related
- 2001-12-28 HR HR20030515A patent/HRP20030515A2/hr not_active Application Discontinuation
- 2001-12-28 KR KR1020097013419A patent/KR100985615B1/ko not_active Expired - Fee Related
- 2001-12-28 EP EP10012572A patent/EP2281828A3/en not_active Withdrawn
- 2001-12-28 NZ NZ551445A patent/NZ551445A/en unknown
- 2001-12-28 DO DO2001P000321A patent/DOP2001000321A/es unknown
- 2001-12-28 PE PE2001001314A patent/PE20020744A1/es not_active Application Discontinuation
- 2001-12-28 JP JP2002555103A patent/JP2005502584A/ja active Pending
- 2001-12-28 EP EP01987457.7A patent/EP1406922B1/en not_active Expired - Lifetime
- 2001-12-28 WO PCT/US2001/049479 patent/WO2002053580A2/en not_active Ceased
- 2001-12-28 UA UA2003077040A patent/UA91321C2/uk unknown
- 2001-12-28 ES ES01987457.7T patent/ES2564552T3/es not_active Expired - Lifetime
- 2001-12-28 EE EEP200300267A patent/EE200300267A/xx unknown
- 2001-12-28 PL PL01365876A patent/PL365876A1/xx not_active Application Discontinuation
- 2001-12-28 BR BR0116587-9A patent/BR0116587A/pt not_active Application Discontinuation
- 2001-12-28 PE PE2011000084A patent/PE20110236A1/es not_active Application Discontinuation
- 2001-12-28 IL IL15639901A patent/IL156399A0/xx active IP Right Grant
- 2001-12-28 SK SK957-2003A patent/SK9572003A3/sk unknown
- 2001-12-28 MX MXPA03005893A patent/MXPA03005893A/es active IP Right Grant
- 2001-12-28 CN CN2011102274750A patent/CN102319421A/zh active Pending
- 2001-12-28 RS YU53103A patent/RS52276B/sr unknown
- 2001-12-31 UY UY27111A patent/UY27111A1/es unknown
-
2002
- 2002-01-02 AR ARP020100003A patent/AR035412A1/es unknown
- 2002-01-03 SV SV2002000814A patent/SV2003000814A/es not_active Application Discontinuation
-
2003
- 2003-06-11 IL IL156399A patent/IL156399A/en not_active IP Right Cessation
- 2003-06-11 ZA ZA2003/04551A patent/ZA200304551B/en unknown
- 2003-06-13 IS IS6843A patent/IS6843A/is unknown
- 2003-06-24 NO NO20032912A patent/NO332038B1/no not_active IP Right Cessation
- 2003-07-25 BG BG108030A patent/BG108030A/bg unknown
-
2009
- 2009-09-10 JP JP2009209009A patent/JP2010031017A/ja active Pending
-
2010
- 2010-06-09 CL CL2010000606A patent/CL2010000606A1/es unknown
-
2013
- 2013-04-25 JP JP2013092598A patent/JP6114099B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-15 JP JP2015141106A patent/JP2015221816A/ja active Pending
-
2016
- 2016-05-20 PH PH12016500941A patent/PH12016500941A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005502584A5 (https=) | ||
| EA029025B1 (ru) | Аналоги глюкагона, проявляющие активность на рецепторе gip | |
| DE69427650T2 (de) | Verbindungen mit wachstumshormon-freisetzenden eigenschaften | |
| DE60128916T2 (de) | Neues, physiologisch aktives peptid und dessen verwendung | |
| KR100880201B1 (ko) | 에리트로포이에틴-응답 세포, 조직 및 기관의 보호, 회복및 향상 | |
| DE60219006T2 (de) | Modifizierte und stabilisierte GDF Propeptide und ihre Verwendungen | |
| DE69032600T3 (de) | Rekombinanter abkömmling des menschlichen faktors iii | |
| Probstmeier et al. | Galectin‐3, a β‐galactoside‐binding animal lectin, binds to neural recognition molecules | |
| JP7649624B2 (ja) | 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生 | |
| EA010371B1 (ru) | Тканевые протективные цитокины для защиты, восстановления и стимуляции реактивных клеток, тканей и органов | |
| JPH07500839A (ja) | インスリン様成長因子およびアナログの適用による網膜ニューロン障害の治療 | |
| DD299197A5 (de) | Vom hirn stammender neurotropher faktor | |
| DE69132814T2 (de) | Neues insulinähnliches wachstumsfaktor bindendes protein igfbp-5 | |
| US7795215B2 (en) | MNTF peptides and compositions and methods of use | |
| CN101268099A (zh) | 用于治疗性干预的y4选择性受体激动剂 | |
| JP2020509011A (ja) | エリスロポエチン由来ペプチドの細胞損傷防止に対する効果を介した活用 | |
| HUE025347T2 (en) | NOGO receptor binding protein | |
| DE60207043T2 (de) | Histidin-reiches glykoprotein (hrgp) zur inhibierung der angiogenese | |
| ES2457398T3 (es) | Variantes de eritropoyetina | |
| DE69132813T2 (de) | Genetisches igfbp-5 rodierendes material | |
| WO2001092298A9 (de) | MUTEINE EINER KETTE EINES PROTEINS AUS DER SUPERFAMILIE DES WACHSTUMSFAKTORS TGF-$g(b) | |
| CH698246B1 (de) | Test zur Identifizierung von Inhibitoren von Beta-Sekretasen. | |
| CA2580991A1 (en) | Amylin family polypeptide-6 (afp-6) analogs and methods of making and using them | |
| US5350841A (en) | Ganglioside derivatives | |
| JP3903503B2 (ja) | 可溶性ポリペプチド |